1378 related articles for article (PubMed ID: 18502655)
1. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
2. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
3. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
5. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
Fernandes HB; Baimbridge KG; Church J; Hayden MR; Raymond LA
J Neurosci; 2007 Dec; 27(50):13614-23. PubMed ID: 18077673
[TBL] [Abstract][Full Text] [Related]
7. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
9. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
10. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
11. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; LlinĂ¡s R; Kristal BS; Hayden MR; Bezprozvanny I
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
[TBL] [Abstract][Full Text] [Related]
12. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
14. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
Li L; Murphy TH; Hayden MR; Raymond LA
J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
[TBL] [Abstract][Full Text] [Related]
15. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
Bezprozvanny I
Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
Zeron MM; Hansson O; Chen N; Wellington CL; Leavitt BR; Brundin P; Hayden MR; Raymond LA
Neuron; 2002 Mar; 33(6):849-60. PubMed ID: 11906693
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
[TBL] [Abstract][Full Text] [Related]
18. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
19. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
Li L; Fan M; Icton CD; Chen N; Leavitt BR; Hayden MR; Murphy TH; Raymond LA
Neurobiol Aging; 2003 Dec; 24(8):1113-21. PubMed ID: 14643383
[TBL] [Abstract][Full Text] [Related]
20. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]